Treatments targeting EGFR, including tyrosine kinase inhibitors (TKIs) like gefitinib and erlotinib, as well as monoclonal antibodies such as cetuximab, are employed to combat cancers exhibiting EGFR anomalies [65]. The gene discussed is EGFR; the disease is cancer.